Table 4 Drug-drug interactions and predicted plasma levels of oral anticoagulants and targeted cancer therapies
From: Management of atrial fibrillation in patients taking targeted cancer therapies
| Â | Oral Anticoagulants | |||||
|---|---|---|---|---|---|---|
Warfarin | Dabigatran | Rivaroxaban | Apixaban | Edoxaban | ||
Tyrosine Kinase Inhibitors | Afatinib | Â | Â | Â | Â | Â |
Axitinib | Â | Â | Â | Â | Â | |
Bosutinib | Â | Â | Â | Â | Â | |
Cabozantinib | Â | Â | Â | Â | Â | |
Ceritinib | ↑OAC levels |  | ↑OAC levels | ↑OAC levels |  | |
Crizotinib | ↑OAC levels | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | |
Dasatinib | ↑OAC levels & effect | ↑OAC effect | ↑OAC levels & effect | ↑OAC levels & effect | ↑OAC effect | |
Erlotinib | ↑OAC levels |  |  |  |  | |
Gefitinib | ↑OAC effect |  |  |  |  | |
Ibrutinib | ↑OAC effect | ↑OAC levels & effect* | ↑OAC levels & effect* | ↑OAC levels & effect* | ↑OAC levels & effect* | |
Imatinib | ↑OAC levels & effect |  | ↑OAC levels | ↑OAC levels |  | |
Lapatinib |  | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | |
Lenvatinib | Â | Â | Â | Â | Â | |
Nilotinib | ↑OAC levels | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | |
Osimertinib | ↑OAC levels |  | ↑OAC levels | ↑OAC levels |  | |
Pazopanib | Â | Â | Â | Â | Â | |
Ponatinib | Â | Â | Â | Â | Â | |
Regorafenib | ↑OAC effect |  |  |  |  | |
Ruxolitinib | Â | Â | Â | Â | Â | |
Sorafenib | ↑OAC levels & effect |  |  | ↑OAC levels |  | |
Sunitinib |  | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | |
Vandetanib |  | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | ↑OAC levels* | |
- Drug-drug interactions are predicted based on pharmacokinetics, given the limited data available from patient studies
- Underlined = "Alter combination"
-
